AI Article Synopsis
Article Abstract
Introduction: Concurrent chemoradiotherapy with high-dose (HD) cisplatin is the standard treatment for locally advanced head and neck squamous cell carcinoma (LA-HNSCC). Due to the higher treatment-related adverse effects with standard therapy, alternative regimens (non-standard therapy), namely, lower dose weekly cisplatin, carboplatin/paclitaxel, or cetuximab are considered. There is, however, no consensus on non-standard regimens. We aimed to investigate the efficacy and safety profile of these regimens.
Methods: This single centre retrospective cohort study included all consecutive adult patients with newly diagnosed LA-HNSCC treated with either standard or non-standard regimens between January 2016 and April 2021. The primary outcome was 2-year failure-free survival (FFS). The secondary outcomes included acute toxicities, hospitalisation rates, dose modifications, treatment failure rates (TFR), and overall survival.
Results: About 235 patients were included in the final analysis; median age was 61 years (IQR 55-67), and 87% were male. Most had oropharyngeal tumours (85.5%) and p16-positivity was frequent (80%). About 56% received non-standard regimens: weekly cisplatin = 79 and non-cisplatin = 48. These patients had higher Charlson Comorbidity Index (CCI; p < .001) and lower European Cooperative Oncology Group (ECOG)-0 (p = .003). There was no difference in 2-year FFS (hazard ratio [HR] = 1.16; 95% confidence interval - [CI] 0.65-2.05), hospitalisation and grade-3 toxicity rates between the two regimens. Nausea and vomiting were lower in the non-standard regimen (3.0% vs. 16%, p < .001). Dose reductions, adjusted for age, sex, and CCI, were less likely in the non-standard regimen (OR = 2.36; 95%-CI: 1.01-5.49, p = .007).
Conclusions: We demonstrated similar efficacy of lower dose weekly cisplatin and carboplatin/paclitaxel regimens and better safety profile of weekly cisplatin compared to standard HD cisplatin regimens for LA-HNSCC. Multicenter randomised control trials are required in HD cisplatin-ineligible patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9875652 | PMC |
| http://dx.doi.org/10.1002/cnr2.1674 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Does maximal effort cytoreductive surgery after 6-cycles of chemotherapy play a role in the management of advanced ovarian cancer?
Arch Gynecol Obstet
December 2024
Northern Gynaecology Oncology Centre, Queen Elizabeth Hospital, Gateshead, UK.
Article Synopsis
- The study focuses on the management of advanced ovarian cancer, highlighting the gold standard of complete removal of visible tumors, and exploring the implications of delayed cytoreductive surgery for patients who cannot undergo initial or interval surgery.
- It is a retrospective analysis of patients with stage IIIC or higher ovarian cancer at the Northern Gynaecological Oncology Centre over six years, comparing survival outcomes between two groups: those who received only chemotherapy and those who had delayed surgery after six cycles.
- Of the 89 patients evaluated, most completed six cycles of chemotherapy without surgery, while a smaller group underwent delayed surgery, suggesting a potential benefit from this approach in specific cases where initial surgery was not feasible.
Research Progress of γδT Cells in Tumor Immunotherapy.
Cancer Control
September 2024
Department of Clinical Laboratory, The First Affiliated Hospital of Kunming Medical University, Kunming, China.
γδT cells are special innate lymphoid cells, which are not restricted by major histocompatibility complex (MHC). γδT cells mainly exist in human epidermis and mucosal epithelium. They can secrete a variety of cytokines and chemokines involved in immune regulation, and produce effective cytotoxic responses to cancer cells.
View Article and Find Full Text PDFPerformance Challenges in a Newly Established Clean Room at Omid Hospital, Isfahan, Iran: A Descriptive Study.
J Res Pharm Pract
January 2024
Department of Clinical Pharmacy and Pharmacy Practice, Isfahan University of Medical Sciences, Isfahan, Iran.
Objective: This study aimed to comprehensively assess the challenges faced by a newly established clean room in the oncology center of Omid Hospital, Isfahan, Iran, one of the first of its kind in the country. The research also sought to identify the underlying causes of these challenges and propose potential solutions to address them.
Methods: A 6-month cross-sectional study was conducted from December 2021 to May 2022.
The prevalence, clinical reasoning and impact of non-standard anti-tuberculosis regimens at the initial prescription.
Sci Rep
March 2024
College of Medicine, National Taiwan University, Taipei, Taiwan.
Regarding clinically-concerning non-standard initial anti-tuberculous (TB) regimens, few studies have examined their prevalence, risk factors and impacts. We recruited patients with drug susceptible TB and non-standard initial anti-TB regimens (NSTB group) and matched them with patients with standard initial regimens (STB group) in a 1:1 ratio. The risk factors and outcomes were analyzed.
View Article and Find Full Text PDFLocalised breast cancer: neoadjuvant chemotherapy impact evaluation on the pathological complete response (PCR) in a lower middle-income country.
Ecancermedicalscience
December 2023
Department of Medical Oncology, Mohammed VI University Hospital, 2360 Marrakech-principal, Morocco.
Introduction: Neoadjuvant chemotherapy followed by surgery remains the current recommended therapeutic strategy for the management of locally advanced breast cancer. The standard chemotherapy protocol is sequential with anthracycline followed by taxanes. However public hospitals in Morocco are confronted with a shortage in healthcare products.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!